Peripheral Arterial Disease – Epidemiology – Europe
DRG Epidemiology’s coverage of peripheral arterial disease (PAD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PAD for each country, as well as annualized case counts projected to the national population.
Most patient populations in the mature pharmaceutical markets are forecast over a period of 20 years; in other countries, forecasts cover a 10-year period. In addition to forecasting prevalent patient populations, we calculate the number of drug-treatment opportunities in specific lines of therapy in the mature pharmaceutical markets.
DRG Epidemiology’s PAD forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people living with PAD?
Of all people with PAD, how many in each country have been formally diagnosed?
Of all people diagnosed with PAD, how many in the mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PAD over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the mature pharmaceutical markets. These patient flows are provided at the regional level but may be requested for any specific country or forecast year.
DRG Epidemiology provides at least ten years of forecast data for the following PAD patient populations:
Peripheral Arterial Disease - Epidemiology - Europe
Total Prevalence of Peripheral Arterial Disease per 100 People Aged 40+ in 2020 and 2030ttttttttt
Relative Sizes of the Factors Contributing to the Trend in Total Prevalent Cases of Peripheral Arterial Disease over the Next Ten Yearsttttttttt
Number of Total Prevalent Cases of Peripheral Arterial Disease in 2030 Prevented in the Countries Under Study Due to Trends in Riskttttttttt
Total Incident Cases
Total Prevalent Cases
Diagnosed Prevalent Cases
Prevalent Cases by Severity
Lifetime DALYs Gained
Studies Included in the Analysis of Peripheral Arterial Disease
Studies Excluded from the Analysis of Peripheral Arterial Disease
Risk/Protective Factors for Peripheral Arterial Disease
Alison Isherwood, M.Sc., M.Res., Ph.D.
Alison Isherwood, M.Sc., M.Res., Ph.D., is a senior director on the Epidemiology team at Clarivate. She specializes in female cancers, biomarker, and infectious disease epidemiology, particularly involving the impact of vaccination. She holds a B.Sc. in medical microbiology, a master’s degree in research in the life sciences (specializing in virology and parasitology), and an M.Sc. in epidemiology, all from the University of Edinburgh. She also holds a Ph.D. in molecular virology from the University of Reading in England.